Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that it has commercially launched Gianvi (Drospirenone and Ethinyl Estradiol) Tablets, the Company's generic version of Bayer's Yaz® Tablets. Total sales of Yaz® Tablets were approximately $782 million in the United States, for the twelve months that ended December 31, 2009, based on IMS sales data.
As the first company to file an Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.
As previously announced, Teva has the right to launch an authorized generic version of the product, supplied by Bayer, in July 2011.
Teva Pharmaceutical Industries Ltd.